Zinc Gluconate Lozenges For Common Cold. A Double-blind Clinical Trial
Notes for this study:
|| Rate and percentage. Placebo: 16 (32.0 Zinc: 10 (20.0) Duration (median and IQR days). Placebo: 0.0 (0.0–1.0) Zinc: 0
|Number of Subjects
In a randomized, double-blind, placebo-controlled trial, 100 healthy children 8-13 years old were given 15 mg of zinc bis-glycinate chelate once daily or placebo for 3 months.
The primary outcome was the occurrence of any symptom of cold at any time during the 3-months. There was notably less cough and rhinorrhoea but more fever in the zinc group, but none of the differences were statistically significant. There was less vomiting, diarrhea, antibiotic use, school absence, or cold-related school absence, though none of these differences were statistically significant either. The number of participants with at least one symptom of coughs, fever, and rhinorrhoea wasn't different between groups, but the number experiencing 2 or 3 was nonsignificantly lower.
Coughs and rhinorrhoea lasted for significantly less time in the zinc groups.